Literature DB >> 3773916

IgG subclass levels in the serum of patients with primary immunodeficiency.

R J Wedgwood, H D Ochs, V A Oxelius.   

Abstract

Serum IgG subclass levels are reported on 70 patients with known primary immunodeficiency syndromes. Analysis of the data on the 28 patients with common variable immunodeficiency suggest that the deficit in subclasses is not generally proportionate. Some subclasses appear to be more strongly affected than others. The pattern suggests a hierarchical involvement with the order: IgG4 greater than IgG2 greater than IgG1 greater than IgG3. There appears to be a closer relationship between IgG1 and IgG3 levels than between IgG2 and IgG3 or IgG1 and IgG2 levels. The data are consistent with the hypothesis that there is a sequential increasing impediment of the programmed cascade for downstream heavy chain constant region gene rearrangements.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3773916

Source DB:  PubMed          Journal:  Monogr Allergy        ISSN: 0077-0760


  4 in total

1.  Changes in serum immunoglobulin patterns in adults with common variable immunodeficiency.

Authors:  M Seligmann; P Aucouturier; F Danon; J L Preud'Homme
Journal:  Clin Exp Immunol       Date:  1991-04       Impact factor: 4.330

2.  IgG subclass-containing cells in the human large bowel of normal controls, non-IBD colitis, and ulcerative colitis.

Authors:  M Iizuka
Journal:  Gastroenterol Jpn       Date:  1990-02

3.  Development of hypogammaglobulinaemia in a patient with common variable immunodeficiency.

Authors:  A Ishizaka; M Nakanishi; S Yamada; Y Sakiyama; S Matsumoto
Journal:  Eur J Pediatr       Date:  1989-12       Impact factor: 3.183

4.  Immunoglobulin deficiencies and susceptibility to infection among homozygotes and heterozygotes for C2 deficiency.

Authors:  Chester A Alper; Jianhua Xu; Katherine Cosmopoulos; Brian Dolinski; Rosanne Stein; Gabriel Uko; Charles E Larsen; Devendra P Dubey; Peter Densen; Lennart Truedsson; Gunnar Sturfelt; Anders G Sjöholm
Journal:  J Clin Immunol       Date:  2003-07       Impact factor: 8.317

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.